S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
AAPL   318.73 (+1.11%)
FB   222.14 (+0.17%)
MSFT   167.10 (+0.56%)
GOOGL   1,479.52 (+2.02%)
AMZN   1,864.72 (-0.70%)
CGC   24.89 (+2.43%)
NVDA   249.28 (+0.14%)
BABA   227.43 (+1.56%)
MU   57.66 (-0.03%)
GE   11.81 (-0.25%)
TSLA   510.50 (-0.58%)
AMD   50.93 (+2.33%)
T   38.38 (+0.92%)
ACB   2.13 (-0.93%)
F   9.16 (-0.11%)
NFLX   339.67 (+0.31%)
PRI   128.43 (+0.05%)
BAC   34.71 (-0.03%)
GILD   62.98 (-0.35%)
DIS   144.33 (-0.54%)
Log in

NASDAQ:CLLS - Cellectis Stock Price, Forecast & News

$18.24
-0.21 (-1.14 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$18.09
Now: $18.24
$18.67
50-Day Range
$13.90
MA: $16.75
$19.21
52-Week Range
$9.50
Now: $18.24
$20.84
Volume243,000 shs
Average Volume130,675 shs
Market Capitalization$774.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.43 million
Book Value$10.82 per share

Profitability

Net Income$-78,690,000.00
Net Margins-446.75%

Miscellaneous

Employees161
Market Cap$774.29 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.


Stock Trades Or Predictions (Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

Cellectis (NASDAQ:CLLS) Frequently Asked Questions

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.89) by $0.51. The biotechnology company had revenue of $10.21 million for the quarter, compared to analyst estimates of $1.40 million. Cellectis had a negative net margin of 446.75% and a negative return on equity of 21.03%. View Cellectis' Earnings History.

When is Cellectis' next earnings date?

Cellectis is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Cellectis.

What price target have analysts set for CLLS?

6 brokers have issued 1-year target prices for Cellectis' shares. Their forecasts range from $20.00 to $73.00. On average, they anticipate Cellectis' share price to reach $40.40 in the next twelve months. This suggests a possible upside of 121.5% from the stock's current price. View Analyst Price Targets for Cellectis.

What is the consensus analysts' recommendation for Cellectis?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.

Has Cellectis been receiving favorable news coverage?

News headlines about CLLS stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellectis earned a daily sentiment score of -3.6 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Cellectis.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in December. As of December 31st, there was short interest totalling 245,100 shares, a drop of 22.7% from the December 15th total of 316,900 shares. Based on an average daily volume of 121,400 shares, the days-to-cover ratio is presently 2.0 days. Approximately 0.6% of the shares of the company are short sold. View Cellectis' Current Options Chain.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Calyxt (CLXT), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), Exelixis (EXEL), Editas Medicine (EDIT), Alibaba Group (BABA), WEC Energy Group (WEC) and Neurocrine Biosciences (NBIX).

Who are Cellectis' key executives?

Cellectis' management team includes the folowing people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.34%).

Which major investors are buying Cellectis stock?

CLLS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB.

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $18.24.

How big of a company is Cellectis?

Cellectis has a market capitalization of $774.29 million and generates $21.43 million in revenue each year. The biotechnology company earns $-78,690,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Cellectis employs 161 workers across the globe.View Additional Information About Cellectis.

What is Cellectis' official website?

The official website for Cellectis is http://www.cellectis.com/.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]


MarketBeat Community Rating for Cellectis (NASDAQ CLLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel